YU36104A - Kristalna struktura fosfodiesteraza 5 i njihova upotreba - Google Patents

Kristalna struktura fosfodiesteraza 5 i njihova upotreba

Info

Publication number
YU36104A
YU36104A YU36104A YUP36104A YU36104A YU 36104 A YU36104 A YU 36104A YU 36104 A YU36104 A YU 36104A YU P36104 A YUP36104 A YU P36104A YU 36104 A YU36104 A YU 36104A
Authority
YU
Yugoslavia
Prior art keywords
pde5
phosphodiesterase
present
crystal structure
identifying
Prior art date
Application number
YU36104A
Other languages
English (en)
Inventor
David Graham Brown
Colin Roger Groom
Andrew Lee Hopkins
Timothy Mark Jenkins
Sarah Helen Kamp
Margaret Mary O'gara
Heather Joan Ringrose
Colin Mark Robinson
Wendy Elaine Taylor
Original Assignee
Pfizer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Limited filed Critical Pfizer Limited
Publication of YU36104A publication Critical patent/YU36104A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04035—3',5'-Cyclic-GMP phosphodiesterase (3.1.4.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Ovaj pronalazak se odnosi, inter alia na kristalne strukture fosfodiesteraza 5 (PDE5) i PDE5/PDE5 ligand komplekse i njihove upotrebe u identifikovanju PDE5 liganda, uključujući i PDE5 inhibitorska jedinjenja. Ovaj pronalazak se takodje odnosi na postupke za identifikaciju takvih PDE5 inhibitorskih jedinjenja i njihovu upotrebu u medicini. Ovaj pronalazak takodje razmatra i kristali PDE5/PDE5 inhibitor kompleksa.[The present invention relates , inter alia to the crystal structures of a phosphodiesterase 5 (PDE5) and PDE5/PDE5 ligand complex and their uses in identifying PDE5 ligands, including PDE5 inhibitor compounds. The present invention also relates to methods of identifying such PDE5 inhibitor compounds and their medical use. Also contemplated by the present invention are crystals of PDE5/PDE5 inhibitor complexes.
YU36104A 2001-11-02 2002-10-24 Kristalna struktura fosfodiesteraza 5 i njihova upotreba YU36104A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0126417.5A GB0126417D0 (en) 2001-11-02 2001-11-02 Crystal structure

Publications (1)

Publication Number Publication Date
YU36104A true YU36104A (sh) 2006-08-17

Family

ID=9925082

Family Applications (1)

Application Number Title Priority Date Filing Date
YU36104A YU36104A (sh) 2001-11-02 2002-10-24 Kristalna struktura fosfodiesteraza 5 i njihova upotreba

Country Status (13)

Country Link
US (2) US20070015205A1 (sh)
EP (1) EP1468082A1 (sh)
KR (1) KR20050039728A (sh)
CN (1) CN1585821A (sh)
BR (1) BR0213717A (sh)
CA (1) CA2478059A1 (sh)
GB (1) GB0126417D0 (sh)
IL (1) IL163926A0 (sh)
PL (1) PL370513A1 (sh)
RU (1) RU2301259C2 (sh)
WO (1) WO2003038080A1 (sh)
YU (1) YU36104A (sh)
ZA (1) ZA200403198B (sh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005133628A (ru) * 2003-05-01 2007-05-10 Пфайзер Инк. (US) Кристалл pde5, его кристаллическая структура и применение для получения лекарственных средств
EP1627323A4 (en) * 2003-05-06 2008-04-09 New Century Pharmaceuticals ALBUMIN FIXATION SITES FOR EVALUATING DRUG INTERACTIONS OR THE DEVELOPMENT OF MEDICAMENTS BASED ON THEIR ALBUMIN BINDING PROPERTIES
CA2585115A1 (en) * 2003-11-03 2005-05-12 New Century Pharmaceuticals, Inc. Albumin binding sites for evaluating drug interactions and methods of evaluating or designing drugs based on their albumin binding properties
CN101490099B (zh) * 2006-07-12 2013-03-27 诺瓦提斯公司 用于制备隐形眼镜的可光化交联的共聚物
AR064286A1 (es) 2006-12-13 2009-03-25 Quiceno Gomez Alexandra Lorena Produccion de dispositivos oftalmicos basados en la polimerizacion por crecimiento escalonado fotoinducida
CN103865914B (zh) * 2012-12-14 2016-05-25 上海美迪西生物医药股份有限公司 Pde2催化结构域/pde2特异性抑制剂复合物的晶体及其生长方法
KR102141542B1 (ko) 2013-12-31 2020-09-14 엘지디스플레이 주식회사 표시장치
FR3039297B1 (fr) * 2015-07-20 2018-05-18 Roam Data, Inc Lecteur de carte compact
KR102576402B1 (ko) 2016-05-31 2023-09-11 엘지디스플레이 주식회사 액정표시장치

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1038963B1 (en) * 1993-05-27 2009-08-05 Board Of Regents Of The University Of Washington Cyclic GMP-binding, cyclic GMP-specific phosphodiesterase materials and methods
GB9923968D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Therapeutic agents
PL356848A1 (en) * 1999-12-24 2004-07-12 Bayer Aktiengesellschaft Novel imidazo[1,3,5]triazinones and the use thereof

Also Published As

Publication number Publication date
US20040082052A1 (en) 2004-04-29
RU2301259C2 (ru) 2007-06-20
CN1585821A (zh) 2005-02-23
US20070015205A1 (en) 2007-01-18
KR20050039728A (ko) 2005-04-29
GB0126417D0 (en) 2002-01-02
BR0213717A (pt) 2004-08-31
CA2478059A1 (en) 2003-05-08
RU2004113450A (ru) 2005-04-20
IL163926A0 (en) 2005-12-18
ZA200403198B (en) 2005-11-18
EP1468082A1 (en) 2004-10-20
PL370513A1 (en) 2005-05-30
WO2003038080A1 (en) 2003-05-08

Similar Documents

Publication Publication Date Title
MX9700430A (es) El uso de compuestos heterociclicos.
CA2371818A1 (en) Salicylamide-lanthanide complexes for use as luminescent markers
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
MXPA04001348A (es) NUEVOS COMPUESTOS DE FOSFITOS Y SUS COMPLEJOS METaLICOS.
HUP0302792A2 (hu) Dipeptidil peptidáz ciklopropil-kondenzált pirrolidin-bázisú inhibitorai és eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
EP1862457A3 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
DE60016898D1 (de) Phthalamid-lanthanid komplexe zur verwendung als lumineszenzmarker
ATE233762T1 (de) Bicyclische polyamiosaure metallkomplexe, verfahren zu ihrer herstellung und ihre verwendung für medizinische bilderzeugung
DK0662972T3 (da) 3-, 8-substituerede deuteroporphyrinderivater, farmaceutiske midler indeholdende disse og fremgangsmåder til deres fremstilling
GEP20084488B (en) Use of therapeutic agents for treating pain
BG105784A (en) Triazole compounds with dopamine-d3-receptor affinity
BR0210078A (pt) Composto, uso do mesmo, e, formulação farmacêutica
PL373414A1 (en) 8-methoxy-(1,2,4)triazolo(1,5-a)pyridine derivatives and their use as adenosine receptor ligands
WO2002062398A3 (en) Radioactively labelled conjugates of phosphonates
IL133824A0 (en) Tetrazole derivatives, medicaments containing same and use thereof
HK1063787A1 (en) Novel ligand for nicotinic acetylcholine receptorsuseful in therapy
YU36104A (sh) Kristalna struktura fosfodiesteraza 5 i njihova upotreba
CA2443285A1 (en) Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
HUP0102615A2 (hu) 2-(2-Klór-fenil)-3,4-dihidro-2H-pirrol-származékok
IL159993A0 (en) Platinum complexes and their use in cancer treatment
RS20060239A (en) Arylalkylcarbamate derivatives, preparation method thereof and use of same in therapeutics
WO2002013874A8 (de) Verwendung von perfluoralkylhaltigen metallkomplexen als kontrastmittel im mr-imaging zur darstellung von plaques, tumoren und nekrosen
AU2001277549A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of plaques, tumours and necroses
MXPA05010651A (es) Compuestos de pirazol.
AU2003281146A1 (en) Use of metal complexes containing perfluoroalkyl as contrast agents in mr-imaging for the representation of intravascular thrombes